Asia PacificENPublic drug registration overview

India Pharmaceutical Registration Pathway

Market Overview Market profile: India is a global hub for generics and APIs and a fastgrowing domestic medicine market. Price control, clinical trials, import licensing, and local...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.

AI Citation Summary

  • Country: India Pharmaceutical Registration Pathway
  • Product line: Pharmaceuticals
  • Regulator / source: Regulatory maturity: Medium-high. CDSCO regulates new drugs, clinical trials, import registration, and central licensing.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulators typically question safety, efficacy, quality, GMP, BE/clinical evidence, labeling, and risk management. Project plans should reserve at least one deficiency-response cycle and should not treat official target timelines as guaranteed launch dates.
  • Key fees: Marketing authorisation for medicines in India is generally managed by Central Drugs Standard Control Organisation (CDSCO). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://cdsco.gov.in before project launch for current forms, systems, fees, and guidance.
  • Local requirement: Marketing authorisation for medicines in India is generally managed by Central Drugs Standard Control Organisation (CDSCO). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://cdsco.gov.in before project launch for current forms, systems, fees, and guidance.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

India Pharmaceutical Registration Pathway

Market Overview

  • Market profile: India is a global hub for generics and APIs and a fast-growing domestic medicine market. Price control, clinical trials, import licensing, and local manufacturing matter heavily.
  • Regulatory maturity: Medium-high. CDSCO regulates new drugs, clinical trials, import registration, and central licensing.
  • Core decision: Determine whether the product is New Drug, Subsequent New Drug, imported medicine, generic, vaccine/biologic, or clinical trial application.

Regulator

  • Authority: Central Drugs Standard Control Organisation (CDSCO)
  • Official portal: https://cdsco.gov.in

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.

India Pharmaceutical Registration Pathway Drug Registration and Market Access | MedTech Atlas